rss
06-07-2017, 11:51 PM
Third Pole’s On-Demand Portable i**: Interview with Dr. Warren Zapol
https://www.medgadget.com/wp-content/uploads/2017/06/third-pole-prototype-300x200.jpghttps://www.medgadget.com/wp-content/uploads/2017/06/third-pole-prototype.jpg
Inhaled nitric oxide (i**) relaxes blood vessels in the lungs and is an important and life-saving treatment for pulmonary hypertension. Current i** delivery solutions are estimated to cost $2,800 per day*and rely on compressed gas delivery which limits accessibility and applicability of this tech**logy worldwide.
Dr. Warren Zapol (https://www.tech**logyreview.com/s/527986/dr-adventure/) and team, led by his son David Zapol, have launched the company*Third Pole*with tech**logy licensed from*Massachusetts General Hospital*(MGH) with the goal of developing next generation life-*saving therapies capable of serving new cardio-pulmonary markets. Their initial product*leverages an iridium spark electrode, calcium hydroxide scavenger (https://www.ncbi.nlm.nih.gov/pubmed/26136478), and filter to deliver continuous inhaled nitric oxide (**) generated from readily available ambient air. The tech**logy could be integrated with standard ventilators, inhalers, or implantable devices, enabling the use of i** for pulmonary hypertension and other diseases in ways never before seen.
Medgadget had the privilege of interviewing Dr. Zapol, Chairman of the Third Pole Scientific Advisory Board, Director of the Anesthesia Center for Critical Care Research at MGH, and Reginald Jenney Professor of Anesthesia at Harvard Medical School.
William Kethman, MD, Medgadget: What inspired you to develop a portable on-demand i** source?
https://www.medgadget.com/wp-content/uploads/2017/06/WZ-201x300.jpgDr. Warren Zapol, Third Pole:*I was flying from Boston to Los Angeles to visit a colleague, Lou Ignarro, who won the **bel Prize for the discovery of **’s biological role, when I read about **X in smog and read about how NASA flies chase planes through lightning and can measure nitric oxide. This formed the core of the idea. It’s made all around us by electrical discharge in air. In follow-up lab work and testing over several years, it became clear that this unique tech**logy to safely generate ** for inhalation using iridum-electrodes to make clean discharge could also be portable, and bring ** to the rest of the world.
Medgadget: Where you do see this tech**logy being most transformative? Do you think it will unlock therapy for other diseases or patients populations? If so, which?
Dr. Zapol:*Nitric oxide has been used for 1M patients in 27 years. This is the tip of the iceberg. Third Pole’s tech**logy could be accessible to facilities that could **t accommodate tank-based ** and facilities that already offer tank based i** could have more convenient access. The tech**logy has the potential to be transformative in so many ways.
In developed countries, a more convenient and portable tech**logy could bring Third Pole’s product to more settings outside of level III units in apex institutions and regional perinatal centers. I’d like to see i** in community hospitals. If our tech**logy were to make it one day possible for newborns born in a community hospital to start i** therapy without delay or transfer, it could potentially prevent escalation to ECMO. Data has demonstrated that ECMO-eligible infants whose i** treatment started at >24 hours of age were more likely to respond to i**. Moreover, having your baby being transferred potentially hours away from your home can induce increased levels of distress in parents of a NICU baby. There are also a number of developmental benefits can be disrupted if the parents are unable to be consistently present with the patient due to distance of a tertiary facility. Touch is critical for growth, development, communication, and healing.
I always tell people I speak with- “Don’t forget the babies in Uganda.” Our tech**logy can extend i** therapy to a greater degree in emerging markets that lack the with infrastructure to transport, maintain, return and refill tanks of a gaseous pharmaceutical and reliably move around costly fleets of compressed gas cylinders.
Beyond that, there is a lot of exciting research into the potential uses of nitric oxide, and Third Pole’s convenient tech**logy could make them more feasible. We will see i** extend into the ambulatory market, used by people with COPD or other heart and lung diseases at home. Our work points to the need for new PDE inhibitors or pathway modulators to be developed as cardiopulmonary therapies.
Medgadget: What regulatory pathway does Third Pole anticipate for clearance of the tech**logy?
Dr. Zapol:*We will seek device approval as an iridium-electrode ** generator. Because our iridium-based, filtered and scavenged system makes clean **, we expect physicians to use our device with the same indications for which tank-based i** is approved: hypoxic respiratory failure in neonates in the US and additional acute cardiopulmonary conditions in Europe. We will later conduct trials of our tech**logy and seek approval for ambulatory use.
Medgadget: What are some of the challenges you are anticipating as you commercialize the tech**logy?
Dr. Zapol:*As stated above, there are many hospitals both in developed and emerging countries that have never used i**. For many people the cell phone is the only phone they k**w. For many hospitals electrically generated i** will be their introduction to i**.
https://www.medgadget.com/wp-content/uploads/2017/06/divider.jpg
Link: Third Pole… (http://www.pole3.com/)
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=aYfseJNR8k4:DvWFgLrgYdw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=aYfseJNR8k4:DvWFgLrgYdw:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=aYfseJNR8k4:DvWFgLrgYdw:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=aYfseJNR8k4:DvWFgLrgYdw:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/aYfseJNR8k4
https://www.medgadget.com/wp-content/uploads/2017/06/third-pole-prototype-300x200.jpghttps://www.medgadget.com/wp-content/uploads/2017/06/third-pole-prototype.jpg
Inhaled nitric oxide (i**) relaxes blood vessels in the lungs and is an important and life-saving treatment for pulmonary hypertension. Current i** delivery solutions are estimated to cost $2,800 per day*and rely on compressed gas delivery which limits accessibility and applicability of this tech**logy worldwide.
Dr. Warren Zapol (https://www.tech**logyreview.com/s/527986/dr-adventure/) and team, led by his son David Zapol, have launched the company*Third Pole*with tech**logy licensed from*Massachusetts General Hospital*(MGH) with the goal of developing next generation life-*saving therapies capable of serving new cardio-pulmonary markets. Their initial product*leverages an iridium spark electrode, calcium hydroxide scavenger (https://www.ncbi.nlm.nih.gov/pubmed/26136478), and filter to deliver continuous inhaled nitric oxide (**) generated from readily available ambient air. The tech**logy could be integrated with standard ventilators, inhalers, or implantable devices, enabling the use of i** for pulmonary hypertension and other diseases in ways never before seen.
Medgadget had the privilege of interviewing Dr. Zapol, Chairman of the Third Pole Scientific Advisory Board, Director of the Anesthesia Center for Critical Care Research at MGH, and Reginald Jenney Professor of Anesthesia at Harvard Medical School.
William Kethman, MD, Medgadget: What inspired you to develop a portable on-demand i** source?
https://www.medgadget.com/wp-content/uploads/2017/06/WZ-201x300.jpgDr. Warren Zapol, Third Pole:*I was flying from Boston to Los Angeles to visit a colleague, Lou Ignarro, who won the **bel Prize for the discovery of **’s biological role, when I read about **X in smog and read about how NASA flies chase planes through lightning and can measure nitric oxide. This formed the core of the idea. It’s made all around us by electrical discharge in air. In follow-up lab work and testing over several years, it became clear that this unique tech**logy to safely generate ** for inhalation using iridum-electrodes to make clean discharge could also be portable, and bring ** to the rest of the world.
Medgadget: Where you do see this tech**logy being most transformative? Do you think it will unlock therapy for other diseases or patients populations? If so, which?
Dr. Zapol:*Nitric oxide has been used for 1M patients in 27 years. This is the tip of the iceberg. Third Pole’s tech**logy could be accessible to facilities that could **t accommodate tank-based ** and facilities that already offer tank based i** could have more convenient access. The tech**logy has the potential to be transformative in so many ways.
In developed countries, a more convenient and portable tech**logy could bring Third Pole’s product to more settings outside of level III units in apex institutions and regional perinatal centers. I’d like to see i** in community hospitals. If our tech**logy were to make it one day possible for newborns born in a community hospital to start i** therapy without delay or transfer, it could potentially prevent escalation to ECMO. Data has demonstrated that ECMO-eligible infants whose i** treatment started at >24 hours of age were more likely to respond to i**. Moreover, having your baby being transferred potentially hours away from your home can induce increased levels of distress in parents of a NICU baby. There are also a number of developmental benefits can be disrupted if the parents are unable to be consistently present with the patient due to distance of a tertiary facility. Touch is critical for growth, development, communication, and healing.
I always tell people I speak with- “Don’t forget the babies in Uganda.” Our tech**logy can extend i** therapy to a greater degree in emerging markets that lack the with infrastructure to transport, maintain, return and refill tanks of a gaseous pharmaceutical and reliably move around costly fleets of compressed gas cylinders.
Beyond that, there is a lot of exciting research into the potential uses of nitric oxide, and Third Pole’s convenient tech**logy could make them more feasible. We will see i** extend into the ambulatory market, used by people with COPD or other heart and lung diseases at home. Our work points to the need for new PDE inhibitors or pathway modulators to be developed as cardiopulmonary therapies.
Medgadget: What regulatory pathway does Third Pole anticipate for clearance of the tech**logy?
Dr. Zapol:*We will seek device approval as an iridium-electrode ** generator. Because our iridium-based, filtered and scavenged system makes clean **, we expect physicians to use our device with the same indications for which tank-based i** is approved: hypoxic respiratory failure in neonates in the US and additional acute cardiopulmonary conditions in Europe. We will later conduct trials of our tech**logy and seek approval for ambulatory use.
Medgadget: What are some of the challenges you are anticipating as you commercialize the tech**logy?
Dr. Zapol:*As stated above, there are many hospitals both in developed and emerging countries that have never used i**. For many people the cell phone is the only phone they k**w. For many hospitals electrically generated i** will be their introduction to i**.
https://www.medgadget.com/wp-content/uploads/2017/06/divider.jpg
Link: Third Pole… (http://www.pole3.com/)
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=aYfseJNR8k4:DvWFgLrgYdw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=aYfseJNR8k4:DvWFgLrgYdw:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=aYfseJNR8k4:DvWFgLrgYdw:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=aYfseJNR8k4:DvWFgLrgYdw:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/aYfseJNR8k4